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IL-6 concentrations on MBDA score. Thus, MBDA scores 
obtained during TCZ treatment should be interpreted cau-
tiously and in the context of available clinical information.
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Introduction
Tocilizumab (TCZ) is a recombinant, humanized monoclo-
nal antibody that blocks interleukin 6 (IL-6) from binding 
to the soluble and membrane-bound IL-6 receptors (IL-6R) 
and thereby inhibits IL-6-mediated signaling. The clinical 
and radiographic efficacy of TCZ in patients with rheuma-
toid arthritis (RA) has been demonstrated in multiple trials 
[1–5]. TCZ treatment has been shown to have distinctive 
effects on serum biomarkers [2, 5, 6]. For instance, serum 
IL-6 concentrations increase during treatment with TCZ 
[6–8]. In addition, IL-6 is a key stimulator of acute-phase 
reactants [9], including C-reactive protein (CRP) and serum 
amyloid A (SAA), and the inhibition of IL-6R by treatment 
with TCZ leads to a rapid reduction in serum concentra-
tions of CRP and SAA [1, 2, 5, 10].
The use of biologic therapy, alone or in combination 
with disease-modifying antirheumatic drugs such as meth-
otrexate (MTX), allows for rapid and effective suppres-
sion of disease activity (DA) and improvements in clinical 
signs and symptoms and radiographic outcomes. Treatment 
guidelines recommend a treat-to-target strategy, with the 
goal of achieving remission or the lowest attainable disease 
state [11, 12]. Clinical assessment tools can aid physicians 
in reaching this goal by quantifying DA, albeit with varying 
degrees of subjectivity. Objective measures include serum 
Abstract The multi-biomarker disease activity (MBDA) 
score measures 12 proteins involved in the pathophysiol-
ogy of rheumatoid arthritis (RA) to assess disease activity 
(DA). Previous studies demonstrated correlations between 
MBDA and clinical DA scores with some RA therapies. 
In this analysis, the relationship between DA and MBDA 
scores and changes in MBDA component biomarkers were 
evaluated in tocilizumab (TCZ)-treated patients. Patients 
from the ACT-RAY study were included in this analysis if 
they had DA measures and serum collected at pre-specified 
time points with sufficient serum for MBDA testing at ≥1 
visit. Descriptive statistics, associations between outcomes, 
and percentage agreement between DA categories were 
calculated. Seventy-eight patients were included and were 
similar to the ACT-RAY population. Correlations between 
MBDA score and DAS28-CRP were ρ = 0.50 at baseline 
and ρ = 0.26 at week 24. Agreement between low/moder-
ate/high categories of MBDA score and DAS28-CRP was 
observed for 77.1 % of patients at baseline and 23.7 % 
at week 24. Mean changes from baseline to weeks 4, 12, 
and 24 were proportionately smaller for MBDA score than 
DAS28-CRP. Unlike some other MBDA biomarkers, inter-
leukin-6 (IL-6) concentrations increased in most patients 
during TCZ treatment. Correlations and agreement between 
MBDA and DAS28-CRP or CDAI scores were lower at 
week 24 versus baseline. The proportionately smaller 
magnitude of response observed for MBDA score versus 
DAS28-CRP may be due to the influence of the increase in 
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CRP and erythrocyte sedimentation rate (ESR). However, 
their utility in patients with RA may be limited, as they are 
often in the normal range for patients with active RA, pos-
sibly reflecting physiological differences between individu-
als [13, 14].
A multi-biomarker disease activity (MBDA) blood 
test has been developed to analyze 12 protein biomark-
ers, including IL-6, CRP, and SAA, that play a role in the 
pathophysiology of RA [15]. The test uses an algorithm 
that combines the biomarker concentrations to produce a 
DA score on a scale of 1–100. Previous studies of several 
treatments for RA have demonstrated that MBDA scores 
correlate with RA disease activity, as measured by the 
28-joint Disease Activity Score with CRP (DAS28-CRP) 
and the Clinical Disease Activity Index (CDAI) [16, 17].
In view of the potential effects that TCZ has on bio-
markers included in the MBDA test and DAS28-CRP, the 
objective of this analysis was to evaluate the association 
between clinical DA and MBDA scores before and during 
TCZ treatment and to assess the concomitant effect of TCZ 
treatment on the component biomarkers of the MBDA test.
Patients and methods
Participants
Patients with RA participating in the global ACT-RAY 
phase 4 study of inadequate responders to MTX [18] were 
eligible for inclusion in this sub-study if they had provided 
serum samples at baseline and weeks 4, 12, and 24 of ACT-
RAY and had DAS28-ESR or DAS28-CRP measured at 
those visits. Of the patients meeting these criteria, 100 were 
randomly selected to have MBDA assays performed using 
frozen serum samples. All patients in the ACT-RAY trial 
were treated with TCZ 8 mg/kg every 4 weeks, with 1:1 
randomization to continue MTX or receive placebo (PBO). 
This ratio of MTX versus PBO was maintained in the pre-
sent analysis.
Biomarker assays and clinical assessments
Measurement of the 12 biomarkers in the MBDA test and 
calculation of MBDA scores were performed in the devel-
opment laboratory of Crescendo Bioscience, Inc. (South 
San Francisco, California) using the Vectra® DA algo-
rithm, as previously described [15, 17, 19]. MBDA scores 
are reported as integers from 1 to 100, with the following 
categories for DA: low (<30), moderate (30–44), and high 
(>44) [20].
Clinical DA assessments, including swollen joint count 
(28 joints), tender joint count (28 joints), patient global 
visual analog scale (VAS), physician global VAS, and 
high-sensitivity CRP (analyzed centrally), were collected 
as part of the core study for calculation of DAS28-CRP 
and CDAI [21, 22]. DAS28-CRP was selected because 
the MBDA formula is based on this score [17]. CDAI is 
provided as an alternative DA measure without a labo-
ratory parameter. For the present analyses, conservative 
DA thresholds were used for DAS28-CRP: low (≤2.67), 
moderate (2.67 to ≤4.09), and high (>4.09) [23]. The DA 
thresholds used for CDAI were low (≤10), moderate (10 to 
≤22), and high (>22) [24].
Statistical methods
Descriptive statistics at each visit were calculated for 
MBDA score, DAS28-CRP, and CDAI. Percentage change 
from baseline to week 24 was calculated for biomarkers 
of the MBDA test. Spearman’s rank correlation coeffi-
cients were estimated, and the corresponding scatter plots 
were examined to evaluate the association between MBDA 
scores and clinical measures at each time point. Percent-
age agreement between DA categories (low, moderate, and 
high) for each pair of scores (MBDA score and DAS28-
CRP, MBDA score and CDAI, DAS28-CRP and CDAI) 
was evaluated at baseline and week 24.
The analysis of scores at any particular visit was 
restricted to patients with both an MBDA score and a clini-
cal DA score at that visit. Analysis of change from base-
line to a visit was restricted to patients with the required 
measurements at baseline and that visit. No imputation was 
performed for data that were missing due to missed visits 
or incomplete clinical or laboratory information.
Results
Of the 553 intention-to-treat patients from the ACT-RAY 
study, 168 patients were eligible for this analysis, 100 were 
randomly selected, 81 had serum samples available for 
MBDA testing from at least 1 time point, and 78 contrib-
uted scores to the final analysis, although some patients did 
not have biomarker scores at all time points due to insuf-
ficient serum volume. The 78 patients had similar baseline 
demographics and clinical characteristics compared with 
those in the larger study population (Table 1) [18]. Mean 
values (standard deviation) for MBDA score, DAS28-CRP 
and CDAI for the 48 patients with MBDA scores at base-
line were 54.9 (17.30), 5.6 (0.98), and 37.8 (12.29, n = 47), 
respectively.
Figure 1 presents cross-classifications of patients by 
MBDA score, DAS28-CRP, and CDAI categories (low, 
moderate, and high) at baseline and at week 24. Agree-
ments between DAS28-CRP and CDAI were 87.2 % at 
baseline (prior to initiation of TCZ treatment) and 84.5 % 
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at week 24 of TCZ treatment (Fig. 1). Agreement between 
MBDA score and DAS28-CRP was 77.1 % at baseline and 
23.7 % at week 24. Similar results were observed between 
MBDA score and CDAI (72.3 % agreement at baseline and 
21.7 % agreement at week 24). Further analysis showed 
that the level of the correlation between MBDA scores 
and clinical disease assessments also decreased during 
TCZ treatment. Spearman’s rank correlations for DAS28-
CRP versus MBDA score, CDAI versus MBDA score, and 
DAS28-CRP versus CDAI were ρ = 0.50, 0.19, and 0.85, 
respectively, at baseline and varied between 0.19–0.33, 
0.03–0.24, and 0.91–0.93, respectively, for weeks 4 through 
24.
Figure 2 presents the means and 95 % confidence inter-
vals (CIs) for change from baseline to weeks 4, 12 and 
24 for DAS28-CRP and MBDA scores. Both outcomes 
decreased over time, demonstrating improvement in DA. 
However, the MBDA scores decreased proportionately less 
than the DAS28-CRP. To explore why the MBDA score 
changed this way during TCZ treatment, the percentage 
changes in concentration from baseline to week 24 for the 
individual biomarkers of the MBDA score were examined 
Table 1  Demographics and 
baseline characteristics of the 
analysis subset and the core 
study population
BMI body mass index, CDAI Clinical Disease Activity Index, DAS28-CRP 28-joint disease activity score 
with C-reactive protein, ITT intent to treat, SD standard deviation
Characteristic Analysis subset (n = 78) Core study ITT population [18] (n = 553)
Female, n (%) 64 (82.1) 444 (80.3)
Age, mean (SD), years 50.7 (14.40) 53.3 (12.67)
Disease duration, mean (SD), years 8.5 (7.85) 8.2 (8.20)
 <2 years, n (%) 18 (23.1) 144 (21.2)
 2 to <5 years, n (%) 17 (21.8) 129 (26.0)
 5 to <10 years, n (%) 19 (24.4) 163 (23.3)
 ≥10 years, n (%) 24 (30.8) 163 (29.5)
BMI, mean (SD), kg/m2 25.4 (5.00) 26.4 (5.16)
DAS28-CRP, mean (SD) 5.7 (0.91) 5.7 (1.0)
CDAI, mean (SD) [n] 38.4 (12.09) [77] 38.7 (12.65) [547]
Fig. 1  Association between MBDA score and clinical disease activ-
ity at baseline and week 24. CDAI Clinical Disease Activity Index, 
DAS28-CRP 28-joint disease activity score with C-reactive protein, 
MBDA multi-biomarker disease activity. Disease activity thresholds: 
MBDA: low (<30), moderate (30–44), high (>44); DAS28-CRP: low 
(≤2.67), moderate (>2.67 to ≤4.09), high (>4.09); CDAI: low (≤10), 
moderate (>10 to ≤22), high (>22)
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(Fig. 3). Median percentage decreases from baseline to 
week 24 were largest for CRP and SAA. Conversely, IL-6 
concentrations showed a large median percentage increase 
from baseline to week 24.
Discussion
In this post hoc analysis, the associations observed between 
MBDA score and composite clinical DA scores (DAS28-
CRP and CDAI) were weaker during TCZ treatment than at 
baseline, prior to TCZ treatment. Similarly, the agreement 
between categories of MBDA score and clinical DA levels 
was high at baseline and noticeably reduced after treatment 
with TCZ for 24 weeks. In addition, MBDA scores did not 
improve proportionately as much as DAS28-CRP during 
TCZ treatment, which may have contributed to the low on-
treatment correlations between the MBDA and clinical DA 
scores.
The effect of TCZ on MBDA scores during treatment 
observed in this analysis may be explained, at least in part, 
by effects that IL-6 receptor antagonism had on component 
MBDA biomarkers, specifically increases in IL-6 levels 
and decreases in CRP and SAA. The algorithm for calcu-
lating the MBDA score positively weighs these biomarkers 
such that higher values result in higher MBDA scores. Our 
findings suggest that the substantial increases in IL-6 con-
centrations partially countered the decreases in CRP, SAA, 
and other biomarkers, thereby contributing to the propor-
tionately smaller improvements observed in the MBDA 
score, compared with DAS28-CRP and CDAI. This find-
ing is consistent with that of a previous study in Japanese 
patients with established RA, in which 24 and 52 weeks 
of TCZ treatment led to increased IL-6 concentrations in 
the majority of patients, and to smaller median percentage 
decreases in MBDA score compared with DAS28-ESR and 
CDAI [25].
Potential limitations of this sub-study include timing of 
biomarker sampling, use of concomitant MTX, sample size, 
and missing data. The timing of serum collection relative to 
dosing may affect the biomarker concentrations distinctly 
from the clinical assessments. For example, it is known 
that CRP levels can fluctuate between TCZ infusions at 
the 4 mg/kg dose [1, 3]. However, with the 8 mg/kg dose 
used here, decreases in CRP concentration are generally 
sustained throughout the dosing interval [18]. The present 
analyses are aggregated results across patients, regardless 
of randomized treatment; therefore, they do not address the 
influence of MTX in combination with TCZ versus TCZ 
alone on the MBDA score or biomarkers. However, previ-
ous studies have demonstrated that changes in biomarker 
serum concentrations (CRP decreases and IL-6 increases) 
occur during TCZ treatment with or without concomitant 
Fig. 2  Mean (95 % CI) change from baseline in DAS28-CRP and 
MBDA score. MBDA scores (at weeks 12 and 24) and DAS28-CRP 
(at weeks 4, 12, and 24) were statistically significantly improved 
from baseline, based on 95 % CI being entirely <0. BL baseline, 
DAS28-CRP 28-joint disease activity score with C-reactive protein, 
MBDA multi-biomarker disease activity
Fig. 3  Percentage changes in MBDA biomarker concentrations from 
baseline to week 24. Percentage changes in concentrations of indi-
vidual biomarkers from baseline to week 24 for patients with MBDA 
results at both time points (n = 35). Biomarkers are sorted by median 
percentage change from baseline. Each box represents the interquar-
tile range (IQR; 25th to 75th percentiles), with the median indicated 
by a line, the mean indicated by a diamond, and the whiskers extend-
ing to the last data values within the 1.5 × IQR range; circles indicate 
outliers (defined as points beyond the 1.5 × IQR). Seven values with 
large percentage increases from baseline to week 24 were analyzed, 
but are not shown: 2 for SAA (1728 % and 2427 %), 1 for CRP 
(3247 %), 2 for EGF (1840 % and 4000 %), and 2 for IL-6 (1940 % 
and 2772 %). BL baseline, CRP C-reactive protein, EGF epidermal 
growth factor, IL interleukin, MMP matrix metalloproteinase, SAA 
serum amyloid A, TNFR tumor necrosis factor receptor, VCAM vas-
cular cell adhesion molecule, VEGFA vascular endothelial growth 
factor α, YKL-40 human cartilage glycoprotein 39
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MTX [5–8, 18, 26]. Finally, this analysis included only 
a subset of patients from the ACT-RAY trial, and some 
patients were missing data. Comparison of the demograph-
ics and baseline disease characteristics of the present cohort 
to the full study population demonstrated that the two were 
quite similar, supporting that the analysis cohort was rep-
resentative of the full study population. Sensitivity analy-
ses conducted to examine the influence of MBDA scores 
that were not included in these analyses due to insufficient 
serum volume for individual biomarker confirmation indi-
cated that conclusions were robust with respect to these 
values. Additional studies may aid understanding of how 
these findings generalize to other patients.
In conclusion, this analysis found that MBDA score, 
DAS28-CRP, and CDAI all detected decreases in DA 
during 24 weeks of treatment with TCZ. The observed 
decreases were proportionately smaller for MBDA scores, 
which underestimated clinical response to TCZ treatment. 
This finding may reflect the ways that the TCZ mechanism 
of action generally increases serum concentrations of IL-6 
while decreasing CRP and SAA concentrations. Further 
research is needed to fully understand how to best inter-
pret MBDA scores in patients receiving TCZ. In view of 
the present findings, MBDA test results should be inter-
preted cautiously and in the context of all available clinical 
information to best manage patients with RA during TCZ 
treatment.
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